OBJECTIVE: To evaluate the effect of 4 antiarrhythmic treatment protocols on number of ventricular premature complexes (VPC), severity of arrhythmia, heart rate (HR), and number of syncopal episodes in Boxers with ventricular tachyarrhythmias. DESIGN: Randomized controlled clinical trial. ANIMALS: 49 Boxers. PROCEDURE: Dogs with > 500 VPC/24 h via 24-hour ambulatory ECG (AECG) were treated with atenolol (n = 11), procainamide (11), sotalol (16), or mexiletine and atenolol (11) for 21 to 28 days. Results of pre- and posttreatment AECG were compared with regard to number of VPC/24 h; maximum, mean, and minimum HR; severity of arrhythmia; and occurrence of syncope. RESULTS: Significant differences between pre- and posttreatment number of VPC, severity of arrhythmia, HR variables, or occurrence of syncope were not observed in dogs treated with atenolol or procainamide. Significant reductions in number of VPC, severity of arrythmia, and maximum and mean HR were observed in dogs treated with mexiletine-atenolol or sotalol; occurrence of syncope was not significantly different between these 2 treatment groups. CONCLUSIONS AND CLINICAL RELEVANCE: Treatment with sotalol or mexiletine-atenolol was well tolerated and efficacious. Treatment with procainamide or atenolol was not effective.
OBJECTIVE: To evaluate the effect of 4 antiarrhythmic treatment protocols on number of ventricular premature complexes (VPC), severity of arrhythmia, heart rate (HR), and number of syncopal episodes in Boxers with ventricular tachyarrhythmias. DESIGN: Randomized controlled clinical trial. ANIMALS: 49 Boxers. PROCEDURE: Dogs with > 500 VPC/24 h via 24-hour ambulatory ECG (AECG) were treated with atenolol (n = 11), procainamide (11), sotalol (16), or mexiletine and atenolol (11) for 21 to 28 days. Results of pre- and posttreatment AECG were compared with regard to number of VPC/24 h; maximum, mean, and minimum HR; severity of arrhythmia; and occurrence of syncope. RESULTS: Significant differences between pre- and posttreatment number of VPC, severity of arrhythmia, HR variables, or occurrence of syncope were not observed in dogs treated with atenolol or procainamide. Significant reductions in number of VPC, severity of arrythmia, and maximum and mean HR were observed in dogs treated with mexiletine-atenolol or sotalol; occurrence of syncope was not significantly different between these 2 treatment groups. CONCLUSIONS AND CLINICAL RELEVANCE: Treatment with sotalol or mexiletine-atenolol was well tolerated and efficacious. Treatment with procainamide or atenolol was not effective.
Authors: Annelies Decloedt; Barbara Broux; Dominique De Clercq; Piet Deprez; Glenn Van Steenkiste; Lisse Vera; Sofie Ven; Gunther van Loon Journal: J Vet Intern Med Date: 2018-02-20 Impact factor: 3.333
Authors: Lance C Visser; Joanna L Kaplan; Satoko Nishimura; Catherine T Gunther-Harrington; Catherine Bélanger; Maureen S Oldach; Joshua A Stern; Mikaela S Mueller Journal: J Vet Intern Med Date: 2018-07-03 Impact factor: 3.333